Cdc23 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the Cdc23 protein, a crucial component of the anaphase-promoting complex/cyclosome (APC/C). The APC/C is a multi-subunit E3 ubiquitin ligase that plays a pivotal role in regulating the cell cycle by targeting specific proteins for degradation via the ubiquitin-proteasome pathway. Cdc23, along with other core subunits, is essential for the proper functioning of the APC/C, which in turn ensures the accurate progression of cells through mitosis and the maintenance of genomic stability. Inhibition of Cdc23 disrupts the activity of the APC/C, leading to the accumulation of key mitotic regulators and interference with the cell cycle progression, particularly in the metaphase-anaphase transition.
Chemically, Cdc23 inhibitors can vary widely in their structures but typically share a common feature of being able to bind to the Cdc23 protein or its interacting partners within the APC/C complex. This binding can occur through various mechanisms, such as direct interaction with the Cdc23 protein or by targeting the interfaces between Cdc23 and other APC/C components, thereby blocking the assembly or function of the complex. The specificity and potency of these inhibitors depend on their molecular configuration, which is often optimized through chemical modifications to enhance their binding affinity and stability. Understanding the structural basis of Cdc23 inhibition is crucial for designing more effective compounds that can selectively target this protein without affecting other cellular processes. Consequently, research into Cdc23 inhibitors focuses heavily on elucidating their binding mechanisms, structure-activity relationships, and the molecular dynamics involved in their interaction with the APC/C complex.
Items 1 to 10 of 11 total
展示:
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | ¥1489.00 ¥12004.00 | 115 | |
硼替佐米是一种蛋白酶体抑制剂,可干扰泛素化蛋白质的降解,有可能导致通常作为降解靶标的蛋白质堆积。 | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | ¥632.00 ¥2933.00 ¥11056.00 | 163 | |
MG132 作为蛋白酶体抑制剂的作用与硼替佐米相似,可导致通常由蛋白酶体降解的蛋白质堆积。Cdc23 作为 APC/C 的一个组成部分,参与蛋白质的泛素化降解。因此,MG132 通过阻止泛素化靶标的蛋白酶体降解,间接抑制了 Cdc23 的功能。 | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | ¥1433.00 ¥6453.00 ¥46143.00 ¥226813.00 | 20 | |
已知 Withaferin A 可通过抑制蛋白酶体的活性来破坏蛋白酶体途径。由于 Cdc23 在 APC/C 中起作用,而 APC/C 可标记蛋白质供蛋白酶体降解,因此 Withaferin A 可通过阻碍 Cdc23 所依赖的降解机制来间接抑制 Cdc23。 | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | ¥1749.00 | 6 | |
塞拉斯特罗是蛋白酶体的抑制剂,可导致泛素化标记的蛋白质降解紊乱。由于 Cdc23 是 APC/C 泛素化蛋白质供蛋白酶体降解的核心功能,因此 Celastrol 可通过阻断降解途径间接抑制 Cdc23 的功能。 | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | ¥1512.00 ¥2426.00 ¥4964.00 ¥5596.00 | 19 | |
环氧美辛是一种特异性蛋白酶体抑制剂,能阻碍泛素化蛋白质的降解。Cdc23 在 APC/C 复合物中的作用是促进蛋白质的泛素化,以便将其销毁。因此,环氧美辛通过阻滞蛋白酶体降解过程间接抑制了 Cdc23。 | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | ¥1862.00 ¥6487.00 | 60 | |
乳胞素是一种蛋白酶体抑制剂,可防止泛素化目标蛋白的降解。Cdc23 参与 APC/C,而 APC/C 对泛素化蛋白质以便蛋白酶体降解至关重要。因此,Lactacystin 的作用可以通过阻断其靶向的降解途径来间接抑制 Cdc23 的功能。 | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | ¥451.00 | ||
卡非佐米(Carfilzomib)是一种选择性蛋白酶体抑制剂,可阻碍蛋白酶体对蛋白质的降解。Cdc23 是泛素化降解蛋白质的 APC/C 的一部分,卡非佐米可通过破坏蛋白酶体降解系统间接抑制 Cdc23。 | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | ¥3159.00 | ||
另一种蛋白酶体抑制剂奥罗佐米(Oprozomib)可通过阻止泛素化蛋白质的降解而导致其积累。由于 Cdc23 对于 APC/C 标记蛋白酶体降解蛋白的作用至关重要,因此奥罗佐米可通过抑制蛋白酶体间接抑制 Cdc23 的功能。 | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | ¥1805.00 ¥3385.00 | ||
地兰佐米是一种蛋白酶体抑制剂,可破坏泛素化蛋白质的降解途径。通过抑制蛋白酶体,Delanzomib 间接抑制了 Cdc23,因为蛋白酶体降解过程是 APC/C 功能的核心,而 Cdc23 是 APC/C 的一部分。 | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | ¥3509.00 ¥8112.00 | ||
伊沙佐米是一种蛋白酶体抑制剂,能阻碍泛素化过程中靶标蛋白的降解。由于 Cdc23 在 APC/C 中起促进泛素化以便蛋白酶体降解的作用,因此 Ixazomib 通过阻碍蛋白酶体降解机制间接抑制了 Cdc23。 |